Ami Fadia
Stock Analyst at Needham
(4.49)
# 297
Out of 5,147 analysts
349
Total ratings
48.88%
Success rate
26.47%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Buy | $150 → $145 | $102.02 | +42.13% | 28 | Feb 26, 2026 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $18 → $17 | $10.60 | +60.38% | 23 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $46 → $44 | $28.54 | +54.17% | 40 | Feb 25, 2026 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | $225 | $163.89 | +37.29% | 19 | Feb 23, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $187 → $185 | $132.25 | +39.89% | 17 | Feb 12, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $460 → $510 | $336.75 | +51.45% | 17 | Feb 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $210 → $235 | $190.02 | +23.67% | 35 | Jan 12, 2026 | |
| GHRS GH Research | Maintains: Buy | $19 → $29 | $14.85 | +95.29% | 3 | Jan 6, 2026 | |
| COGT Cogent Biosciences | Reiterates: Hold | n/a | $38.85 | - | 24 | Dec 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $28 → $29 | $24.56 | +18.08% | 12 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $44 | $30.10 | +46.18% | 4 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $8 | $3.49 | +129.23% | 10 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $3.63 | +230.58% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $4.99 | +120.44% | 20 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | n/a | $191.82 | - | 43 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $26.86 | +30.31% | 1 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 | $5.73 | +406.11% | 21 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $240 → $320 | $13.80 | +2,218.84% | 2 | Feb 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $63 → $75 | $21.91 | +242.31% | 7 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $23 | $0.26 | +8,406.62% | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $13.22 | +376.55% | 5 | Sep 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $33.86 | - | 9 | Oct 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.19 | +1,748.74% | 4 | Jan 3, 2018 |
Revolution Medicines
Feb 26, 2026
Maintains: Buy
Price Target: $150 → $145
Current: $102.02
Upside: +42.13%
Day One Biopharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $18 → $17
Current: $10.60
Upside: +60.38%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Buy
Price Target: $46 → $44
Current: $28.54
Upside: +54.17%
Axsome Therapeutics
Feb 23, 2026
Reiterates: Buy
Price Target: $225
Current: $163.89
Upside: +37.29%
Neurocrine Biosciences
Feb 12, 2026
Maintains: Buy
Price Target: $187 → $185
Current: $132.25
Upside: +39.89%
Praxis Precision Medicines
Feb 4, 2026
Maintains: Buy
Price Target: $460 → $510
Current: $336.75
Upside: +51.45%
Jazz Pharmaceuticals
Jan 12, 2026
Maintains: Buy
Price Target: $210 → $235
Current: $190.02
Upside: +23.67%
GH Research
Jan 6, 2026
Maintains: Buy
Price Target: $19 → $29
Current: $14.85
Upside: +95.29%
Cogent Biosciences
Dec 8, 2025
Reiterates: Hold
Price Target: n/a
Current: $38.85
Upside: -
ACADIA Pharmaceuticals
Nov 6, 2025
Maintains: Buy
Price Target: $28 → $29
Current: $24.56
Upside: +18.08%
Oct 29, 2025
Maintains: Buy
Price Target: $43 → $44
Current: $30.10
Upside: +46.18%
Oct 28, 2025
Maintains: Buy
Price Target: $6 → $8
Current: $3.49
Upside: +129.23%
Oct 13, 2025
Initiates: Buy
Price Target: $12
Current: $3.63
Upside: +230.58%
Sep 30, 2025
Reiterates: Buy
Price Target: $11
Current: $4.99
Upside: +120.44%
Sep 24, 2025
Reiterates: Hold
Price Target: n/a
Current: $191.82
Upside: -
May 28, 2025
Initiates: Buy
Price Target: $35
Current: $26.86
Upside: +30.31%
May 2, 2025
Reiterates: Buy
Price Target: $29
Current: $5.73
Upside: +406.11%
Feb 1, 2021
Maintains: Outperform
Price Target: $240 → $320
Current: $13.80
Upside: +2,218.84%
Jan 21, 2021
Downgrades: Market Perform
Price Target: $63 → $75
Current: $21.91
Upside: +242.31%
Oct 1, 2020
Maintains: Market Perform
Price Target: $15 → $23
Current: $0.26
Upside: +8,406.62%
Sep 17, 2020
Maintains: Outperform
Price Target: $64 → $63
Current: $13.22
Upside: +376.55%
Oct 1, 2018
Upgrades: Market Perform
Price Target: n/a
Current: $33.86
Upside: -
Jan 3, 2018
Initiates: Outperform
Price Target: $22
Current: $1.19
Upside: +1,748.74%